aa 8-1會期部長業務報告-書面報告.pdf

81
1 主席、各位委員女士、先生: 今天, 大院第 8 屆第 1 會期社會福利及衛生環境委員會召 開全體委員會議, 文達 承邀列席報告,內心感到非常榮幸。 衛生署以「落實品質、提升效率、均衡資源、關懷弱勢」作 為施政願景,期促進及保護全民健康福祉,讓全民能活得更長壽、 更快樂。 現在謹就「傳染病之防治」、「健全醫療體系」、「全民健 保改革」、「食品藥物管理」、「民眾健康促進」、「醫藥生技 研發」、「國際衛生參與」等項重要工作,報告近期主要施政成 果及未來之重要施政規劃,敬請各位 委員不吝惠予指教: 壹、近期主要施政成果 一、傳染病之防治 (一) 流感大流行之因應: 1. 100 7 1 日至 101 2 19 日止,累計 1,118 例流感 併發症確定病例,較去年同期之 1,644 例為低,感染病毒 型別以 B 型居多。 2. 辦理 100 年度流感疫苗接種計畫,採購 266 7,665 劑疫 苗,並自 100 10 1 日開打,施打對象包括 65 歲以上 長者、安養等機構之住民、罕見疾病、重大傷病、6 個月 以上至國小四年級學童、醫事防疫人員及禽畜養殖等高危 險群;截至 100 2 13 日止,完成接種約 257.4 萬劑, 使用率達 97.5%

Upload: lyu-jh

Post on 22-Nov-2015

43 views

Category:

Documents


5 download

TRANSCRIPT

  • 1

    8 1

    ()

    1. 100 7 1 101 2 19 1,118 1,644 B

    2. 100 266 7,665 100 10 1 65 6 100 2 13 257.4 97.5%

  • 2

    3. 25% 100 12 1 101 3 31

    4. 1 101 1 3

    2 16 24

    288 86

    3

    4 101 2 17 2,856

    5

    6 9 1 2 ICU

  • 3

    3 /4

    () 1. 71

    100 58 3 101 2 19 11

    2. 100 71

    3. 71

    4. 100

    5.

  • 4

    5 100

    ()

    1. 1001012191,5431,165 149 99 95 24 4411 1 10 13 (101)(100)

    2.

    3. 100 9

    1 100 9 13 100 11 21 10 20

  • 5

    100 6 1 10 21 28 10 11

    210 100 20

    4. 101 1

    2

    3

  • 6

    4

    5

    6

    ()

    1.

    2. (DOTS)100 14,607 90%

    3. (MDR) 96 5 100 100 212

    4. 100 4,842 99 98

    ()

    1. 3

  • 7

    0800-010-569

    2. 100 12 21 () 928 374 1 100 1 12 28 8,751 349 90%

    3. 100 1 12 7 5,040

    4. 96 100 45 100 12 10,240

    ()

    1. 100 100

  • 8

    490 100 10 100%

    2. 99 2011 Asia Pacific Hand Hygiene Excellence Award 323 100 7 311

    3.

    4. carbapenem

    5. 100 100 33 44

  • 9

    ()

    1. (OPV) 100 9 Tdap-IPV

    2. 5 99 (PCV)101 PCV 5 4.3

    3. 100 10 75

    4. /

    ()

    1. 100 9 16

  • 10

    1

    2

    3 63

    50 4

    2. 98

    100 12 191 19 79 24 55 112 191

    3.

    1 9 17 24

  • 11

    2 13 8

    () 1.

    99 7 1 100 82 204 520

    2. 100 39 601

    3. 14 100 12 136 2 1,000

    4.

  • 12

    100 12 48 103 1 1

    5. 100 19

    6. 100 100 5 45 7 40

    () 1. 9

    19,143 4

    2. 110 105 96 1 4,131 100 3 6,628 94 71.5% 100 5%

  • 13

    3. /100 6.51 16.54

    ()

    1. 100 22 300 100 12 123,748 480,195 3.88 43.37%

    2. 97 7 4 99 1,696 95%100 12 1,211 1,164 96.12%99 27 100%100 12 40 39 97.5%

    3. 99 3,889 10

  • 14

    16.8 98 4,063 10 17.6 174 4.3% 86 10 11 100 1-11 3,102 99 494 14%

    () 1.

    505 238 7 14

    2. 100 136 4 73 5

    3. /58

    4. 1 10

  • 15

    (2) 3 1

    2

    3

    () 1. 6

    11 2. 100 1 1

    200

    3. 100

    4.

    5. 1100

  • 16

    83 37

    2100 11 1

    3 100 100 8

    4100 15

    6. 1 100 225 5 295 100

    2,918 ( 1,450 1,468 ) 3100 69

    2,488 101 80 4 100

    101

    7.

  • 17

    1003248()1553.4

    8. 10092839

    () 1.

    2.

    3.

  • 18

    4.

    5. 6

    () 1. 1

    100 12 276

    2 100 12 208

    3 100 12 150

    2. 100 12 IC 32

    3. 100 12 198 175

  • 19

    () 1.

    2. 100 85 3 0,524 3,655 7,248 1 8,813 948 5 6,700 4,480

    3.

    1100 619 3

    2() 115 135 6 62 1

    3 64 79 1 8

    4. 24

  • 20

    100 301 275 91.4%

    5. 100 776100 32 27

    6. HIS 100 48 32 (PACS)100 3,364

    () 1. 1

    2(22 )(63 )(368

    ) 3()

    4

  • 21

    2. 1

    99 100 12 99 99 100 12 4,330 99 100 1 5,117

    2() 99 5100 8

    3. 1 1

    97 2.3%98 5.7%99 16.3% 100 21%

    2 100 61,675 97 3.5

  • 22

    3 6,346 45 CDR

    2 100 99 100 30

    4. 7 7 8

    5. 98 7 23

    1 99 35 2.98%100 ( 1 )

  • 23

    100 11

    2 100 4 101 7,000

    3 100 7 1,900 1017

    4()()

    5

    6 98 9 100 11

  • 24

    81 225

    ()

    1. 99 4 1 100 12 62

    2. 100 1 26

    3. () 100 12 17.69

  • 25

    4. 100 12 680 2.72%

    5. 7 100 12 1

    ()

    1. 1(Tw-DRGs)

    299 1 155 100 1 164 17% 1,029 60% 5 100 1 18

  • 26

    DRG

    3(Tw-DRGs)

    4 100 1 11 4.39 4.17 5.01% 4 5,474 4 5,314 160 0.35%

    2. 1100

    2 100 2 23 3

  • 27

    25 7 15 100 7 1 103 6 30 101 1 1 103 12 31 3

    3

    3. 100 14.78 100 1 1 17% 2 3 4 101 21.4 100 9 16 17 101 9.099 12.389 100 8 RBRVS 37 100 9 11

  • 28

    101 3

    4. (1)(2)(3) 3 100 377.2

    ()

    1. 100 12 307 226

    2. 1100 12

    3,872 2.41 18.7 43.79 2,646 1,806

    2100 100 12 1.48 3.5

  • 29

    3. 100 12 5,128 1 4,078

    4.

    100 12

    118 17.8

    2 16.9 3

    5.1

    5. (IDS) 48

    ()

    1. 90

  • 30

    99 12 20 5

    2. 99 150() 100 ()

    3.

    4. 98 12 100 190 55 0.099 5%

    () 1. 100 1

    4 100 1 26 1 2

    2.

  • 31

    1

    2

    3 30 16

    4

    5

    6

  • 32

    101 2 19 1668 ( 108 )

    ()

    1. 100 481 46 2,110 200 100 12 145

    2. 100 55 481

    () 1. 1100 259

    2100

    3,141 2,955 94.1%

    3 100 1 1

  • 33

    100 42 0,774

    4 100 3 20() 100 12 31 17,188 3 12 3 26 ()

    5 101 18

    2.

    1100 5 28

  • 34

    5 100 5 31 614 8 1

    2 100 5 31 7 20 4 9,652 4,076 2 9,337 6 11 100 7 28 5723.2617 18.7948 5704.4669 100 7 29

    3 5 28 7 25 131 4,150 100 1,099

  • 35

    4 100 7 20 49 3,180 20

    5 31 34 100 6 22

    6 100 7 13 (TDI) 100 10

  • 36

    7

    393 4,266

    3. 1

    99 9 9 0991301731 100 1 1 101 4 30 100 12 606 99 11 29 0991302917 101 4 30

    2 100 9 28

    ()

  • 37

    1. cGMP 100 12 162 10 3 22 145 GMP 34 PIC/S GMP

    2. 100 1,041 203 20 201 1 2 600 8 5 1

    3. 99 1 100 12 1 6,562 4 7,358.3 99 1 13.9% 100 12 4.95%

    4. (1)

    (2)

  • 38

    (3) 100 140 30 27

    (4) 100 826 163 663 51

    (5) 100 284

    5. GMP 116 100 GMP 60

    6. 100 262 13

    7. 100 385 2,346.9

    8. 100 7 20

    9. 100 8 29 100 12 1 100 67

    10. 18

    11.100 10 15 16 100

  • 39

    31 51 7

    12.Journal of Traditional and Complementary MedicineJTCM 100 10 10

    13.100 2

    () 1. (1)

    100 121 99 67

    (2)

    (3) (DMF)100 6 21 (DMF)

    (4) 100

  • 40

    12 (General Clinical Research Center,GCRC)

    (5) 100 11 1 101 1

    2. (1)

    (2)

    () 1.

    100 15,247 143 0.94%

    2. 100 16,351 99 1 8,792 13.0%

    3. 100 6 2 4 6 14

  • 41

    4. 1 2 98 11 10

    ()

    1. 100 12 431 100 3 3 96 100 12 6 1

    () 1. 10 1 99

    153 1 98.3%100 1 10 153 94.05% 99 100 100 10 1,015 101

  • 42

    2. 100 1 11 1

    1,656 300 19 1,613 3,206 4,059 1,639 100 1 12 19 7,789 3,206

    3. 100 1 12 1 461 608 5,821

    4. 100 12 158 71.4%99 67.2% 1 99 58.5% 100 61.8%99 11 24 100 5 11 100 12 1,548 99.8%

    5.

  • 43

    28 4 1 10 50 99 1.090 100 1.079 16 1.134 18

    6. 99 12 8 100 4 7

  • 44

    100 1 1 100 12 29 3 4

    ()

    1. 4 5100 1 12 35 2,375 97.4% 98%

    2. 99 100 1 10 42 101 100 1 12 3 4 17 9,898 91.38% 97%

    3. 5 1 99 27 7,639 100 1 10 25 4,971 100 22 2,661152

    4. 7 7 99 1031 1 98.3%100 1 10 84 80.5% 100

  • 45

    5. 22 1 6 14 2 4 42

    6. 99 100 26 22 4 8 99 100 2 4,400 99 100 2 3

    7. 99 3 12 5,054 100 1 10 2,039

  • 46

    8. e 100 1 12 39 735 3,045 31 Teens 9 1,981 19 87 113 2 6,264 62 51 414 msn 217

    ()

    1. 40 64 3 1 55 65 1 99 178 100 1 11 170

    2. 3 103 6 166 14 416 582

    3. 18 62.3%

  • 47

    44.6% 4. 20

    22 7 5 3,843 2 3,958 3 6,418 90%

    5. 687 1,986 2 5

    6. 45 16 18 9 2

    7.

    8. 100 536 1,400

    9. 483

  • 48

    100 174 101 101 186 22 100 6,532 4,239

    10. 2011 Diabetes Education and Prevention 4,000

    11. 100 126 2 1,401 6 3,357 50 33 22 2,881 12 5,305 65

    12. 100 9 65 81 100 1 12 50 69 42.6 50-69 76.4 65

  • 49

    537 100 1 10 3,959

    13. 100 1222 1,333 477 26%99 100 60%

    14. 99 100 100 12 13 101 1 19 7 20 105 186 11 15 10 3 3

    15.

  • 50

    WHO-99 100 9 20 101 20

    16. 100 12 22 929 3 424

    ()

    1. 18 99 64.1% 100 65.1%

    2. 91 22

  • 51

    1 8,970

    3. 8 45 100 12 30 101

    4. 100 16 104 107 4

    5. 100 13

    6. AFHC 100 12 7 11 AFHC2

  • 52

    30 2 34 9 3,000

    7. 100 1 12 2 417

    8. 94 100 29 100 12 19

    9. 96 100 100 12 46

    10. 100 3 1

    11. 1 100 12 76 WHO

  • 53

    100 6 19 101 20

    2 100 12 4 Health Care Without HarmHCWHThe First Global Climate and Health Summit WHO TF on HPH and Environment 12 6 HCWH UNFCCC 17 WHO Dr.Maria NeiraHCWH Josha Karliner 50

    3 100 12 8 UNFCCC 17 Climate Change and Public Health: Healthy Climate, Healthy People, Healthy Economy WHO TF on HPH and Environment WHO The First Global Climate and Health Summit

  • 54

    12. 96

    100 12 7,411 303

    13. 3,696

    14. 100 100 1 460 92 604 ( 39.84%) 126

    () 1. 22 100

    60 600 22

  • 55

    2.

    3.

    4.

    5. 100 12 31 1 1,880 72 1,104

    () 1. 100

    99 19.8% 19.1%99 9.1% 8.2%

    2. 100 1 12 38 1,864 1 130 8,770 796 647

    3. 100

  • 56

    4. 100 101 53 32

    5. 100 85 448 44

    6. 100 183 3 5412

    7. 100 1 12 8,567 50

  • 57

    8. 100 1 12 9 8,486 1,957 100110108,922

    9. 49 100 12 953 9 8,267 9,706 3 6,746 3 87.64%( 5,912)

    10. 98 6 4 100 12 112 2,223

    ()

    1. 97 174.4 99 171.3 1.8% 97 10 94.4 99 93.9 0.5% 104 98 10%

    2. 92 96 41.1% 93 97 42.3% 1.2%

  • 58

    58.1% 59.2% 1.1% 3. 100

    1 12 431 214 55.7 76.4 84.9 101 1 12 4,320 9,360 2,584 1,641 1 6,078 1,319 1,591

    4. 100 36 6 HPV100 1 12 6.1

    5. 100 HPV 3,654 3 HPV 48% 1,980 3 HPV 14%

    6. 228 69

    7. 100

  • 59

    100 8 1 97 39 8

    8. 69 100 1 12 2 99 1 42% 98 39% 3%

    ()

    1. 100 12 765 54 100%

    2. 5 1 4

    () 1. DBPR104 99

    7 30 11 23 FDA

  • 60

    2. DBPR108

    3. 8 50 33 100 9

    4. H5N1 1 1 100 6 99 8 2

  • 61

    5. B 100

    6 17 100 7 22 B

    6. /

    7. AURORA Imaging Technology, Inc.

    8.

  • 62

    ()

    1. 64 2005 14 10

    2. (WHO) 100 5 16 6 (Mr. Burci) 4 Burci (take note of)

    3. 100 10

  • 63

    4. APEC (HWG)(2011-2012)(Health Policy Dialogue) 100 3 9 9

    5. APECRFID APEC 100 7 5 6 170 32 APEC 13

    6. 100 9 24 25 2011 210

    () 1.

  • 64

    3 100 12 19 9 13 (LNSP)

    2. 100 7 449

    3. 6000

    4. (TaiwanIHA)(AMDA) 8 1 9 130

    ()

    1.

  • 65

    2.

    3. 100 23 146

    4. 100 6 26 8 1 2

  • 66

    ()100 51 1,443 66 582 4

    1. (1)

    (2) (3) (4) 2. (1)

    (2)

  • 67

    (3) (4) (5)

    1. APEC

    2. 3. (1) (2) (3) (4)

    1. (1) (2) (3) 2. (1)101

  • 68

    (2) 3. (1) 2

    (2) 20 (3) (4)

    1. 2. 55 64 3.

    4. 5.

    6. HPV

    7.

    1. 2. CDC 3.

  • 69

    4. Gastein European Health Forum 5.

    11 45

  • 70

    96 98 100

    1.

    2.

    3. 4.

    2143 1500-1700

  • 71

    1.

    2. 3. 4. 5.

    1.

    2.

  • 72

    IDS

    3. (101-105 )

    4.

    1.

    2. 101

    1. 99 4 1

    2.

  • 73

    1.

    6 ()

    2. 36

    DRG

    1. DRG

    2.

  • 74

    100 1 26

    30

    1. 3

    2.

    3.

  • 75

    10-15 4.

    1. 2. 3.

    1. 71

    2. 71

  • 76

    PCV 102-104 PCV

  • 77

    MIT

  • 78

    1.

    2. 290

    3.

    4. 101 6

    5. 100 101 102 101

  • 79

    102

    101

  • 80

  • 81